SCHEMBL29453088

SCHEMBL29453088

COC(=O)c1cc(F)cc(Br)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.62
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA14 Q9ULX7 2/20 0.48
KDM4E B2RXH2 4/20 0.47
LMNA P02545 3/20 0.47
L3MBTL1 Q9Y468 3/20 0.47
XDH P47989 2/20 0.47
POLB P06746 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
GAA P10253 1/20 0.47
NFKB1 P19838 1/20 0.47
GFER P55789 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
FUT7 Q11130 1/20 0.47
MEN1 O00255 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2825430 1.00 NOTUM (0.62) NOTUMCA12CA1CA2CA7
SCHEMBL22400441 0.93 NOTUM (0.55) NOTUMCA12CA1CA2CA7
SCHEMBL29528596 0.93 NOTUM (0.55) NOTUMCA12CA1CA2CA7
SCHEMBL521670 0.86 CA1 (0.58) NOTUMCA12CA1CA2CA7
Methyl 3,5-Dibromobenzoate SCHEMBL2408987 0.86 NOTUM (0.67) NOTUMCA12CA1CA2CA7
SCHEMBL184614 0.86 NOTUM (0.67) NOTUMCA12CA1CA2CA7
SCHEMBL1401499 0.86 CA1 (0.58) NOTUMCA12CA1CA2CA7
SCHEMBL22400347 0.85 NOTUM (0.51) NOTUMCA12CA1CA2CA7
SCHEMBL16684548 0.85 NOTUM (0.48) NOTUMCA12CA1CA2CA7
SCHEMBL22400306 0.84 NOTUM (0.54) NOTUMCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4735431-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2026-05-06 EP disclosed
WO-2025006568-A2 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. (US) 2025-01-02 WO disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 US disclosed
EP-4055016-A1 GPR52 MODULATOR COMPOUNDS Heptares Therapeutics Limited (GB) 2022-09-14 EP disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 US disclosed
WO-2022129047-A2 NOVEL MODULATORS OF THE NMDA RECEPTOR H. LUNDBECK A/S (DK) 2022-06-23 WO disclosed
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof CYTOKINETICS, INC. (US) 2022-04-12 US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 NOTUM 1931/4885CA12 4676/4885CA1 3966/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 NOTUM 1931/4885CA12 4676/4885CA1 3966/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 NOTUM 1931/4885CA12 4676/4885CA1 3966/4885
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 NOTUM 1931/4885CA12 4676/4885CA1 3966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.